A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.
- Resource Type
- Article
- Source
- International Journal of Gynecological Cancer; Apr2024, Vol. 34 Issue 4, p627-630, 4p
- Subject
- Language
- ISSN
- 1048891X